Interleukin-1 antagonism in acute gout: Is targeting a single cytokine the answer?

Arthritis and Rheumatism

Volumn 62, Issue 10, 2010, Pages 2845-2849

  Neogi, Tuhina ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALGRANULIN A; CALGRANULIN B; CANAKINUMAB; COLCHICINE; CORTICOSTEROID; CORTICOTROPIN; INDOMETACIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; TRIAMCINOLONE; TRIAMCINOLONE ACETATE; TUMOR NECROSIS FACTOR ALPHA;

DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDITORIAL; GOUT; HUMAN; PRIORITY JOURNAL; RECURRENCE RISK; RISK REDUCTION; TREATMENT OUTCOME;

ACUTE DISEASE; GOUT; GOUT SUPPRESSANTS; HUMANS; INTERLEUKIN-1BETA; RECEPTORS, INTERLEUKIN-1;

EID: 77957675505     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.27635     Document Type: Editorial

References (28)

1. Neogi T, Hunter DJ, Chaisson CE, Allensworth-Davies D, Zhang YQ. Frequency and predictors of inappropriate management of recurrent gout attacks in a longitudinal study. J Rheumatol 2006;33:104-9.
2. Kim SY, Choi HK. Gout and quality of life. J Rheumatol 2009;36:865-8.
3. Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, et al, for the National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008;58:26-35.
4. Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Saag KG. Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD). Rheumatology (Oxford) 2005;44:1038-42.
5. Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-24.
6. Sutaria S, Katbamna R, Underwood M. Effectiveness of interventions for the treatment of acute and prevention of recurrent gout - a systematic review. Rheumatology (Oxford) 2006;45:1422-31.
7. Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallelgroup, dose-comparison colchicine study. Arthritis Rheum 2010;62:1060-8.
8. Schlesinger N. Overview of the management of acute gout and the role of adrenocorticotropic hormone. Drugs 2008;68:407-15.
9. Man CY, Cheung IT, Cameron PA, Rainer TH. Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial. Ann Emerg Med 2007;49:670-7.
10. Janssens HJ, Janssen M, van de Lisdonk EH, van Riel PL, van Weel C. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet 2008;371:1854-60.
11. Alloway JA, Moriarty MJ, Hoogland YT, Nashel DJ. Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis. J Rheumatol 1993;20:111-3.
12. Siegel LB, Alloway JA, Nashel DJ. Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of acute gouty arthritis. J Rheumatol 1994;21:1325-7.
13. Janssens HJ, Lucassen PL, Van de Laar FA, Janssen M, Van de Lisdonk EH. Systemic corticosteroids for acute gout. Cochrane Database Syst Rev 2008:CD005521.
14. Arromdee E, Michet CJ, Crowson CS, O'Fallon WM, Gabriel SE. Epidemiology of gout: is the incidence rising? J Rheumatol 2002;29:2403-6.
15. Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol 2004;31:1582-7.
16. Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Schumacher HR Jr, Saag KG. Gout epidemiology: results from the UK General Practice Research Database, 1990-1999. Ann Rheum Dis 2005;64:267-72.
17. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006;440:237-41.
18. Goldbach-Mansky R, Dailey NJ, Canna SW, Gelabert A, Jones J, Rubin BI, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1β inhibition. N Engl J Med 2006;355:581-92.
19. Hoffman HM, Throne ML, Amar NJ, Sebai M, Kivitz AJ, Kavanaugh A, et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 2008;58:2443-52.
20. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009;360:2416-25.
21. Wong M, Ziring D, Korin Y, Desai S, Kim S, Lin J, et al. TNFα blockade in human diseases: mechanisms and future directions. Clin Immunol 2008;126:121-36.
22. So A, De Smedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007;9:R28.
23. Initial phase 3 studies results for rilonacept in the prevention of gout flares in patients initiating uric acid-lowering therapy and the treatment of patients in the midst of an acute gout attack investor teleconference June 9, 2010. URL: http://files.shareholder.com/downloads/REGN/941483174x0x380925/ e99d3c78-f180-4597-a98d-fc1ce20abe49/REGN-Rilonacept-Call-Presentation.pdf.
24. Terkeltaub R, Sundy JS, Schumacher HR, Murphy F, Bookbinder S, Biedermann S, et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis 2009;68:1613-7.
25. Schumacher HR Jr, Sundy JS, Terkeltaub R, Knapp HR, Mellis S, Soo Y, et al. Placebo-controlled study of rilonacept for gout flare prophylaxis during initiation of urate-lowering therapy [abstract]. Arthritis Rheum 2009;60 Suppl:S410-1.
26. So A, De Meulemeester M, Pikhlak A, Yucel AE, Richard D, Murphy V, et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum 2010;62:3064-76.
27. Schlesinger N, Lin HY, De Meulemeester M, Rovensky J, Arulmani U, Krammer G, et al. Efficacy of canakinumab (ACZ885) in the prevention of flares in gout patients initiating allopurinol therapy [abstract]. Ann Rheum Dis 2010;69 Suppl 3:121.
28. Kesselheim AS, Solomon DH. Incentives for drug development - the curious case of colchicine. N Engl J Med 2010;362:2045-7.